guidance

https://news.alphastreet.com/benefiting-from-tax-gains-valeant-pharma-swings-to-profit-in-q4/ The company now forecasts full year revenues below its previous expectation

When providing the outlook for 2018, Saunders said that Allergan faces LOE losses in 2018. But still it has got good long-term prospects. Saunders says that current stock price doesn't reflect Allergan's true value. Wall Street gives thumbs up to his speech.

After raising the quarterly dividend recently, Lilly has provided outlook for 2018 and expects recently launched products to drive revenue. Dave Ricks says ""Looking to the future, the potential of our pipeline remains strong."

Cardinal Health (CAH) earnings for the first quarter of 2018 are hurt by restructuring costs from regaining direct distribution of self-manufactured surgeon gloves and higher intangible assets amortization. Despite this, the company reaffirmed its full-year 2018 non-GAAP EPS guidance. Graphical...

Lower costs and expenses aid in a jump in 3Q17 earnings of Baxter. The company posted net income of $251MM or $0.45 per share, on sales of $2.71Bil. Global sales for Hospital Products grew 7% on continued strength in U.S. fluid systems business as well as favorable demand for injectable...

$VRTX Vertex's cystic fibrosis portfolio progression has led the company to increase its guidance of combined R&D and SG&A for the full year 2017.